VI.b
Pulmonary arterial hypertension
May reverse with drug discontinuation. Generally similar to primary PHTn clinically, hemodynamically and on pathology. PMID 23997051. A few cases are thromboembolic in nature (PMID 24881082). Reviews at PMID 29508628, 30545968
Causative drugs
80
Abused drugs/substances (illicit-, street drugs - IV/inhaled)
I.e
I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia (subacute, acute) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis (silicosis, talcosis...) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) IV.g IV - Airway involvement
IV.g - Cough syncope V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.q V - Pleural and/or pericardial involvement
V.q - Empyema V.ab V - Pleural and/or pericardial involvement
V.ab - Pneumothorax, bilateral VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VI.g VI - Pulmonary vasculopathies
VI.g - Foreign body pulmonary vasculopathy (Excipient lung disease) VI.i VI - Pulmonary vasculopathies
VI.i - Acute pulmonary hypertension VI.j VI - Pulmonary vasculopathies
VI.j - Mercury pulmonary embolism VI.r VI - Pulmonary vasculopathies
VI.r - Septic pulmonary embolism VI.t VI - Pulmonary vasculopathies
VI.t - Pulmonary artery aneurysm(s) VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VII.i VII - Mediastinal involvement
VII.i - Mediastinitis VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma VIII.d VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.d - Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway VIII.ai VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ai - Nasal, palatal and/or pharyngeal pathology IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF) IX.s IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.s - Botulism (foodborne-, wound-) IX.ah IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ah - Acute myelopathy (can cause ARF) X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS) X.bb X - Systemic/Distant conditions, syndromes and reactions
X.bb - Foreign body (talc, cornstarch) retinopathy XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.g XI - Miscellaneous
XI.g - Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility) XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.i XII - Cardiovascular involvement / toxicity
XII.i - Endocarditis (infective) XII.v XII - Cardiovascular involvement / toxicity
XII.v - Hypertrophic cardiomyopathy XV.q XV - Pathology
XV.q - Path: Foreign body deposits/granulomatous reaction XV.s XV - Pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma) XV.v XV - Pathology
XV.v - Path: Micronodular organizing pneumonia/BOOP XV.ag XV - Pathology
XV.ag - Path: Foreign body embolism, microangiopathy, vasculopathy XV.al XV - Pathology
XV.al - Path: Pulmonary hypertension incl. angiomatoid vasculopathy XVI.u XVI - Imaging
XVI.u - Imaging: A miliary pattern (diffuse random micronodules) XVI.v XVI - Imaging
XVI.v - Imaging: Centrilobular micronodules (can be diffuse) XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.ae XVI - Imaging
XVI.ae - Imaging: A pattern similar to pneumoconiotic progressive massive fibrosis (PMF) XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf) XVI.ai XVI - Imaging
XVI.ai - Imaging: A 'tree-in-bud' pattern XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo XVII.p XVII - Infections & related conditions
XVII.p - Lung abscess/abscesses (see also VIr) XVII.s XVII - Infections & related conditions
XVII.s - Sternoclavicular septic arthritis XVII.u XVII - Infections & related conditions
XVII.u - Epidural abscess XVII.al XVII - Infections & related conditions
XVII.al - Osteomyelitis (notably of thoracic bones) XVIII.t XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.t - Eye catcher: Purpuric/Ecchymotic/Cyanotic lesions of the earlobes and/or nose XVIII.u XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.u - Eye catcher: Talc retinopathy
I.e - Acute eosinophilic pneumonia (AEP) I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia (subacute, acute) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis (silicosis, talcosis...) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) IV.g IV - Airway involvement
IV.g - Cough syncope V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.q V - Pleural and/or pericardial involvement
V.q - Empyema V.ab V - Pleural and/or pericardial involvement
V.ab - Pneumothorax, bilateral VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VI.g VI - Pulmonary vasculopathies
VI.g - Foreign body pulmonary vasculopathy (Excipient lung disease) VI.i VI - Pulmonary vasculopathies
VI.i - Acute pulmonary hypertension VI.j VI - Pulmonary vasculopathies
VI.j - Mercury pulmonary embolism VI.r VI - Pulmonary vasculopathies
VI.r - Septic pulmonary embolism VI.t VI - Pulmonary vasculopathies
VI.t - Pulmonary artery aneurysm(s) VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VII.i VII - Mediastinal involvement
VII.i - Mediastinitis VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma VIII.d VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.d - Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway VIII.ai VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ai - Nasal, palatal and/or pharyngeal pathology IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF) IX.s IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.s - Botulism (foodborne-, wound-) IX.ah IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ah - Acute myelopathy (can cause ARF) X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS) X.bb X - Systemic/Distant conditions, syndromes and reactions
X.bb - Foreign body (talc, cornstarch) retinopathy XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.g XI - Miscellaneous
XI.g - Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility) XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.i XII - Cardiovascular involvement / toxicity
XII.i - Endocarditis (infective) XII.v XII - Cardiovascular involvement / toxicity
XII.v - Hypertrophic cardiomyopathy XV.q XV - Pathology
XV.q - Path: Foreign body deposits/granulomatous reaction XV.s XV - Pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma) XV.v XV - Pathology
XV.v - Path: Micronodular organizing pneumonia/BOOP XV.ag XV - Pathology
XV.ag - Path: Foreign body embolism, microangiopathy, vasculopathy XV.al XV - Pathology
XV.al - Path: Pulmonary hypertension incl. angiomatoid vasculopathy XVI.u XVI - Imaging
XVI.u - Imaging: A miliary pattern (diffuse random micronodules) XVI.v XVI - Imaging
XVI.v - Imaging: Centrilobular micronodules (can be diffuse) XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.ae XVI - Imaging
XVI.ae - Imaging: A pattern similar to pneumoconiotic progressive massive fibrosis (PMF) XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf) XVI.ai XVI - Imaging
XVI.ai - Imaging: A 'tree-in-bud' pattern XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo XVII.p XVII - Infections & related conditions
XVII.p - Lung abscess/abscesses (see also VIr) XVII.s XVII - Infections & related conditions
XVII.s - Sternoclavicular septic arthritis XVII.u XVII - Infections & related conditions
XVII.u - Epidural abscess XVII.al XVII - Infections & related conditions
XVII.al - Osteomyelitis (notably of thoracic bones) XVIII.t XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.t - Eye catcher: Purpuric/Ecchymotic/Cyanotic lesions of the earlobes and/or nose XVIII.u XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.u - Eye catcher: Talc retinopathy
3
Alemtuzumab
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS) X.an X - Systemic/Distant conditions, syndromes and reactions
X.an - Cytokine release syndrome - Cytokine storm XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS) X.an X - Systemic/Distant conditions, syndromes and reactions
X.an - Cytokine release syndrome - Cytokine storm XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
1
4
Amphetamine (and -derivatives)
I.e
I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm - Vasospastic angina XIV.a XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.a - Methemoglobinemia
I.e - Acute eosinophilic pneumonia (AEP) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm - Vasospastic angina XIV.a XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.a - Methemoglobinemia
1
Antidepressants
I.b
I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.y VI - Pulmonary vasculopathies
VI.y - Pulmonary hypertension of the newborn (Persistent PHT) IX.e IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.e - Disordered breathing pattern - Cheynes-Stokes respiration XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.y VI - Pulmonary vasculopathies
VI.y - Pulmonary hypertension of the newborn (Persistent PHT) IX.e IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.e - Disordered breathing pattern - Cheynes-Stokes respiration XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
2
Benfluorex
V.a
V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
2
Bevacizumab
I.b
I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis III.g III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.g - Bleeding/hemorrhage from/around preexisting lung tumor (Localized AH) III.h III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.h - Major/massive hemoptysis III.k III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.k - Epistaxis IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VIII.o VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.o - Perforation of the nasal septum VIII.r VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.r - Tracheal/large airway necrosis, chondronecrosis, perforation VIII.ab VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ab - Airway (e.g. tracheoesophageal) fistula X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XII.aj XII - Cardiovascular involvement / toxicity
XII.aj - Systemic arterial thrombosis XII.at XII - Cardiovascular involvement / toxicity
XII.at - Aortitis XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf) XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation
I.b - Pneumonitis (ILD) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis III.g III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.g - Bleeding/hemorrhage from/around preexisting lung tumor (Localized AH) III.h III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.h - Major/massive hemoptysis III.k III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.k - Epistaxis IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VIII.o VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.o - Perforation of the nasal septum VIII.r VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.r - Tracheal/large airway necrosis, chondronecrosis, perforation VIII.ab VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ab - Airway (e.g. tracheoesophageal) fistula X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XII.aj XII - Cardiovascular involvement / toxicity
XII.aj - Systemic arterial thrombosis XII.at XII - Cardiovascular involvement / toxicity
XII.at - Aortitis XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf) XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation
1
Bortezomib
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS) X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome) XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic)
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS) X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome) XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic)
2
Bosutinib
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.ao I - Interstitial/parenchymal lung disease
I.ao - Pulmonary infiltrates V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.ae V - Pleural and/or pericardial involvement
V.ae - Pleural effusion, massive VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.ao I - Interstitial/parenchymal lung disease
I.ao - Pulmonary infiltrates V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.ae V - Pleural and/or pericardial involvement
V.ae - Pleural effusion, massive VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
1
Buprenorphine
II.a
II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis) IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
II.a - Pulmonary edema, noncardiogenic (NCPE) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis) IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
2
COVID19 (SARS-CoV2) vaccination/vaccine
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis I.ay I - Interstitial/parenchymal lung disease
I.ay - Unilateral interstitial lung disease II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.m III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.m - Coagulopathy VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.ac VI - Pulmonary vasculopathies
VI.ac - Pulmonary infarction IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis - Myasthenic-like syndrome IX.y IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.y - A flare or relapse of preexisting myasthenia gravis IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF) X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.h X - Systemic/Distant conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive X.aj X - Systemic/Distant conditions, syndromes and reactions
X.aj - Polyarteritis nodosa-like condition X.be X - Systemic/Distant conditions, syndromes and reactions
X.be - A flare of preexisting immune-mediated systemic/rheumatic disease X.bf X - Systemic/Distant conditions, syndromes and reactions
X.bf - Anti-Jo-1 syndrome X.bg X - Systemic/Distant conditions, syndromes and reactions
X.bg - IgA vasculitis X.bh X - Systemic/Distant conditions, syndromes and reactions
X.bh - Protracted, prolonged anaphylaxis XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant) XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis XII.k XII - Cardiovascular involvement / toxicity
XII.k - Constrictive pericarditis - Pericardial thickening XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest XII.q XII - Cardiovascular involvement / toxicity
XII.q - Pericarditis (see also under XIIc) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XII.bf XII - Cardiovascular involvement / toxicity
XII.bf - Myopericarditis (see under XIIc/d/g) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.c XVI - Imaging
XVI.c - Imaging: A mosaic pattern of attenuation XVI.ay XVI - Imaging
XVI.ay - Imaging: Asymmetrical, predominantly unilateral involvement XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis I.ay I - Interstitial/parenchymal lung disease
I.ay - Unilateral interstitial lung disease II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.m III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.m - Coagulopathy VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.ac VI - Pulmonary vasculopathies
VI.ac - Pulmonary infarction IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis - Myasthenic-like syndrome IX.y IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.y - A flare or relapse of preexisting myasthenia gravis IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF) X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.h X - Systemic/Distant conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive X.aj X - Systemic/Distant conditions, syndromes and reactions
X.aj - Polyarteritis nodosa-like condition X.be X - Systemic/Distant conditions, syndromes and reactions
X.be - A flare of preexisting immune-mediated systemic/rheumatic disease X.bf X - Systemic/Distant conditions, syndromes and reactions
X.bf - Anti-Jo-1 syndrome X.bg X - Systemic/Distant conditions, syndromes and reactions
X.bg - IgA vasculitis X.bh X - Systemic/Distant conditions, syndromes and reactions
X.bh - Protracted, prolonged anaphylaxis XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant) XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis XII.k XII - Cardiovascular involvement / toxicity
XII.k - Constrictive pericarditis - Pericardial thickening XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest XII.q XII - Cardiovascular involvement / toxicity
XII.q - Pericarditis (see also under XIIc) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XII.bf XII - Cardiovascular involvement / toxicity
XII.bf - Myopericarditis (see under XIIc/d/g) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.c XVI - Imaging
XVI.c - Imaging: A mosaic pattern of attenuation XVI.ay XVI - Imaging
XVI.ay - Imaging: Asymmetrical, predominantly unilateral involvement XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1
Cabergoline
I.b
I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
I.b - Pneumonitis (ILD) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
1
Carfilzomib
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS) XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia XVII.o XVII - Infections & related conditions
XVII.o - Nocardia pulmonary/systemic infection XXI.a XXI - Rechallenge data
XXI.a - Rechallenge can lead to near-fatal or fatal relapse of AE/ILD XXI.b XXI - Rechallenge data
XXI.b - Rechallenge can lead to relapse of AE/ILD
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS) XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia XVII.o XVII - Infections & related conditions
XVII.o - Nocardia pulmonary/systemic infection XXI.a XXI - Rechallenge data
XXI.a - Rechallenge can lead to near-fatal or fatal relapse of AE/ILD XXI.b XXI - Rechallenge data
XXI.b - Rechallenge can lead to relapse of AE/ILD
1
Catheter ablation for atrial fibrillation
I.y
I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.ao I - Interstitial/parenchymal lung disease
I.ao - Pulmonary infiltrates II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis III.h III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.h - Major/massive hemoptysis III.l III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.l - Alveolar hemorrhage, localized (e.g. lobar) IV.z IV - Airway involvement
IV.z - Bronchial wall erosion/hematoma IV.ah IV - Airway involvement
IV.ah - Bronchopericardial fistula V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion V.n V - Pleural and/or pericardial involvement
V.n - Hemopericardium - Bloody pericardial effusion V.af V - Pleural and/or pericardial involvement
V.af - Pneumopericardium VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.o VI - Pulmonary vasculopathies
VI.o - Air/gas embolism VI.z VI - Pulmonary vasculopathies
VI.z - Pulmonary vein stenosis VI.ac VI - Pulmonary vasculopathies
VI.ac - Pulmonary infarction VI.ae VI - Pulmonary vasculopathies
VI.ae - Pulmonary vein perforation/rupture VII.d VII - Mediastinal involvement
VII.d - Fibrosing mediastinitis VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VIII.b VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.b - Hematoma of/around central airway wall potentially causing UAO VIII.h VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.h - Vocal cord dysfunction, adduction, closure, injury VIII.j VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.j - Laryngeal disorder-Laryngeal nerve palsy (dysphonia, hoarseness) IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis IX.n IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.n - Vagal nerve injury XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.h XI - Miscellaneous
XI.h - Esophageal pathology (erosion, ulcer, tear, rupture, fistula) XI.k XI - Miscellaneous
XI.k - Esophageal hematoma (may cause chest pain and/or tracheal compression) XI.bl XI - Miscellaneous
XI.bl - Pericardial-esophageal fistula XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm - Vasospastic angina XII.aw XII - Cardiovascular involvement / toxicity
XII.aw - Postcardiac/-cardiotomy injury (PCIS-Dressler syndrome) XII.bd XII - Cardiovascular involvement / toxicity
XII.bd - Perforation of the heart - Cardiac rupture XII.bg XII - Cardiovascular involvement / toxicity
XII.bg - Atrio-esophageal fistula XII.bh XII - Cardiovascular involvement / toxicity
XII.bh - Atrial septal defect, acquired XII.bk XII - Cardiovascular involvement / toxicity
XII.bk - Pulmonary vein thrombosis XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa) XV.ah XV - Pathology
XV.ah - Path: Pulmonary congestion XV.ak XV - Pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD) XV.cx XV - Pathology
XV.cx - Path: Pulmonary vein stenosis XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.l XVI - Imaging
XVI.l - Imaging: Peribronchovascular areas of consolidation XVI.bg XVI - Imaging
XVI.bg - Imaging: Pulmonary vein stenosis XVI.bo XVI - Imaging
XVI.bo - Imaging: Localized calcification of pulmonary vein or veins XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.ao I - Interstitial/parenchymal lung disease
I.ao - Pulmonary infiltrates II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis III.h III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.h - Major/massive hemoptysis III.l III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.l - Alveolar hemorrhage, localized (e.g. lobar) IV.z IV - Airway involvement
IV.z - Bronchial wall erosion/hematoma IV.ah IV - Airway involvement
IV.ah - Bronchopericardial fistula V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion V.n V - Pleural and/or pericardial involvement
V.n - Hemopericardium - Bloody pericardial effusion V.af V - Pleural and/or pericardial involvement
V.af - Pneumopericardium VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.o VI - Pulmonary vasculopathies
VI.o - Air/gas embolism VI.z VI - Pulmonary vasculopathies
VI.z - Pulmonary vein stenosis VI.ac VI - Pulmonary vasculopathies
VI.ac - Pulmonary infarction VI.ae VI - Pulmonary vasculopathies
VI.ae - Pulmonary vein perforation/rupture VII.d VII - Mediastinal involvement
VII.d - Fibrosing mediastinitis VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VIII.b VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.b - Hematoma of/around central airway wall potentially causing UAO VIII.h VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.h - Vocal cord dysfunction, adduction, closure, injury VIII.j VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.j - Laryngeal disorder-Laryngeal nerve palsy (dysphonia, hoarseness) IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis IX.n IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.n - Vagal nerve injury XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.h XI - Miscellaneous
XI.h - Esophageal pathology (erosion, ulcer, tear, rupture, fistula) XI.k XI - Miscellaneous
XI.k - Esophageal hematoma (may cause chest pain and/or tracheal compression) XI.bl XI - Miscellaneous
XI.bl - Pericardial-esophageal fistula XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm - Vasospastic angina XII.aw XII - Cardiovascular involvement / toxicity
XII.aw - Postcardiac/-cardiotomy injury (PCIS-Dressler syndrome) XII.bd XII - Cardiovascular involvement / toxicity
XII.bd - Perforation of the heart - Cardiac rupture XII.bg XII - Cardiovascular involvement / toxicity
XII.bg - Atrio-esophageal fistula XII.bh XII - Cardiovascular involvement / toxicity
XII.bh - Atrial septal defect, acquired XII.bk XII - Cardiovascular involvement / toxicity
XII.bk - Pulmonary vein thrombosis XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa) XV.ah XV - Pathology
XV.ah - Path: Pulmonary congestion XV.ak XV - Pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD) XV.cx XV - Pathology
XV.cx - Path: Pulmonary vein stenosis XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.l XVI - Imaging
XVI.l - Imaging: Peribronchovascular areas of consolidation XVI.bg XVI - Imaging
XVI.bg - Imaging: Pulmonary vein stenosis XVI.bo XVI - Imaging
XVI.bo - Imaging: Localized calcification of pulmonary vein or veins XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia
1
Ceftriaxone
I.c
I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils XXIV.h XXIV - Veterinary medicine
XXIV.h - Veterinary: Anaphylaxis/Anaphylactoid reaction
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils XXIV.h XXIV - Veterinary medicine
XXIV.h - Veterinary: Anaphylaxis/Anaphylactoid reaction
1
Chemotherapy, antineoplastic
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP) I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis I.au I - Interstitial/parenchymal lung disease
I.au - The chemotherapy lung II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.c II - Pulmonary edema - Acute lung injury - ARDS
II.c - ARDS and the hemolytic-uremic syndrome (HUS) II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.k IV - Airway involvement
IV.k - Bronchiectasis V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.ab V - Pleural and/or pericardial involvement
V.ab - Pneumothorax, bilateral VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS) XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XII.bv XII - Cardiovascular involvement / toxicity
XII.bv - Atrial fibrillation XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic) XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign) XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable) XV.ak XV - Pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD) XV.am XV - Pathology
XV.am - Path: Thrombosis in pulmonary arterioles/venules XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf) XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan XVI.bw XVI - Imaging
XVI.bw - Imaging: Air or an air crescent around lung tumor or metastase(s) XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma) XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic) XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary) XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis) XIX.g XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.g - BAL: Atypical epithelial cells (at times poetically named
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP) I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis I.au I - Interstitial/parenchymal lung disease
I.au - The chemotherapy lung II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.c II - Pulmonary edema - Acute lung injury - ARDS
II.c - ARDS and the hemolytic-uremic syndrome (HUS) II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.k IV - Airway involvement
IV.k - Bronchiectasis V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.ab V - Pleural and/or pericardial involvement
V.ab - Pneumothorax, bilateral VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS) XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XII.bv XII - Cardiovascular involvement / toxicity
XII.bv - Atrial fibrillation XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic) XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign) XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable) XV.ak XV - Pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD) XV.am XV - Pathology
XV.am - Path: Thrombosis in pulmonary arterioles/venules XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf) XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan XVI.bw XVI - Imaging
XVI.bw - Imaging: Air or an air crescent around lung tumor or metastase(s) XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma) XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic) XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary) XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis) XIX.g XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.g - BAL: Atypical epithelial cells (at times poetically named
2
Chloroquine
I.b
I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF) IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest XII.p XII - Cardiovascular involvement / toxicity
XII.p - QTc prolongation XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XIV.a XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.a - Methemoglobinemia XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF) IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest XII.p XII - Cardiovascular involvement / toxicity
XII.p - QTc prolongation XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XIV.a XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.a - Methemoglobinemia XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1
Cocaine
I.c
I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis (silicosis, talcosis...) I.z I - Interstitial/parenchymal lung disease
I.z - An area or areas of consolidation II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.b III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.b - Pneumorenal syndrome (w/wo ANCAs) III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis III.n III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.n - Alveolar hemorrhage (subclinical, or as a BAL feature) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) IV.o IV - Airway involvement
IV.o - Airway hyperresponsiveness V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.ab V - Pleural and/or pericardial involvement
V.ab - Pneumothorax, bilateral VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.l VI - Pulmonary vasculopathies
VI.l - Acute pulmonary vasoconstriction and PHT VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma VIII.i VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.i - Midline destructive lesions VIII.w VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.w - Uvulitis, uvular edema VIII.ah VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ah - Tracheal polyps VIII.ai VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ai - Nasal, palatal and/or pharyngeal pathology VIII.ak VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ak - Rhinitis medicamentosa VIII.ap VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ap - Airway foreign body IX.k IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.k - Trismus (lockjaw) IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.h X - Systemic/Distant conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) X.x X - Systemic/Distant conditions, syndromes and reactions
X.x - Subclinical ANCA positivity X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS) X.ad X - Systemic/Distant conditions, syndromes and reactions
X.ad - Skin purpura, ecchymoses or necrosis X.as X - Systemic/Distant conditions, syndromes and reactions
X.as - Scleroderma renal crisis XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning XI.ae XI - Miscellaneous
XI.ae - Barotrauma (incl. pneumothorax, pneumomediastinum, interstitial ephysema...) XI.az XI - Miscellaneous
XI.az - Sneezing (may cause pulmonary barotrauma) XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.y XII - Cardiovascular involvement / toxicity
XII.y - Pneumopericardium XII.ae XII - Cardiovascular involvement / toxicity
XII.ae - Aortic dissection XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm - Vasospastic angina XII.aj XII - Cardiovascular involvement / toxicity
XII.aj - Systemic arterial thrombosis XII.ap XII - Cardiovascular involvement / toxicity
XII.ap - Coronary artery dissection XIV.c XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.c - Carboxyhemoglobinemia XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa) XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern XV.s XV - Pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma) XV.w XV - Pathology
XV.w - Path: Pulmonary edema (see also II/IIa) XV.aw XV - Pathology
XV.aw - Path: Skin vasculopathy/vasculitis/fibrin thrombi XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis (silicosis, talcosis...) I.z I - Interstitial/parenchymal lung disease
I.z - An area or areas of consolidation II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.b III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.b - Pneumorenal syndrome (w/wo ANCAs) III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis III.n III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.n - Alveolar hemorrhage (subclinical, or as a BAL feature) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) IV.o IV - Airway involvement
IV.o - Airway hyperresponsiveness V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.ab V - Pleural and/or pericardial involvement
V.ab - Pneumothorax, bilateral VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.l VI - Pulmonary vasculopathies
VI.l - Acute pulmonary vasoconstriction and PHT VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma VIII.i VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.i - Midline destructive lesions VIII.w VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.w - Uvulitis, uvular edema VIII.ah VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ah - Tracheal polyps VIII.ai VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ai - Nasal, palatal and/or pharyngeal pathology VIII.ak VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ak - Rhinitis medicamentosa VIII.ap VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ap - Airway foreign body IX.k IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.k - Trismus (lockjaw) IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.h X - Systemic/Distant conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) X.x X - Systemic/Distant conditions, syndromes and reactions
X.x - Subclinical ANCA positivity X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS) X.ad X - Systemic/Distant conditions, syndromes and reactions
X.ad - Skin purpura, ecchymoses or necrosis X.as X - Systemic/Distant conditions, syndromes and reactions
X.as - Scleroderma renal crisis XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning XI.ae XI - Miscellaneous
XI.ae - Barotrauma (incl. pneumothorax, pneumomediastinum, interstitial ephysema...) XI.az XI - Miscellaneous
XI.az - Sneezing (may cause pulmonary barotrauma) XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.y XII - Cardiovascular involvement / toxicity
XII.y - Pneumopericardium XII.ae XII - Cardiovascular involvement / toxicity
XII.ae - Aortic dissection XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm - Vasospastic angina XII.aj XII - Cardiovascular involvement / toxicity
XII.aj - Systemic arterial thrombosis XII.ap XII - Cardiovascular involvement / toxicity
XII.ap - Coronary artery dissection XIV.c XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.c - Carboxyhemoglobinemia XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa) XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern XV.s XV - Pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma) XV.w XV - Pathology
XV.w - Path: Pulmonary edema (see also II/IIa) XV.aw XV - Pathology
XV.aw - Path: Skin vasculopathy/vasculitis/fibrin thrombi XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections
1
Contraceptive drugs or pills (oral)
I.e
I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) XV.ak XV - Pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
I.e - Acute eosinophilic pneumonia (AEP) VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) XV.ak XV - Pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
1
Crushed tablets -pills (deliberate i.v. injection of)
I.b
I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension X.bb X - Systemic/Distant conditions, syndromes and reactions
X.bb - Foreign body (talc, cornstarch) retinopathy XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.q XV - Pathology
XV.q - Path: Foreign body deposits/granulomatous reaction XVI.u XVI - Imaging
XVI.u - Imaging: A miliary pattern (diffuse random micronodules) XVI.ai XVI - Imaging
XVI.ai - Imaging: A 'tree-in-bud' pattern XVIII.u XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.u - Eye catcher: Talc retinopathy
I.b - Pneumonitis (ILD) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension X.bb X - Systemic/Distant conditions, syndromes and reactions
X.bb - Foreign body (talc, cornstarch) retinopathy XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.q XV - Pathology
XV.q - Path: Foreign body deposits/granulomatous reaction XVI.u XVI - Imaging
XVI.u - Imaging: A miliary pattern (diffuse random micronodules) XVI.ai XVI - Imaging
XVI.ai - Imaging: A 'tree-in-bud' pattern XVIII.u XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.u - Eye catcher: Talc retinopathy
3